PromisDx is focused on validating our proprietary cancer assay via clinical research studies and plan on launching the cancer diagnostic service in 2021, then expanding to new products and indications. Utilizing a proprietary marker with LTE-qMSP platform, PromisDx builds its pipeline of diagnostic products for the early detection of other cancers.
Promis Diagnostics’ colon cancer test is a stool-based test for screening and diagnosis of cancer. The assay is designed to be an easy, accurate, and affordable test for early colorectal cancer detection. The test detects methylation of DNA, specific to adenomatous polyps and colon cancer. In a clinical study, stool-based colon test gave an overall sensitivity of 90.2% with a specificity of 90.2%.
Promis Diagnostics’ bladder cancer test is a urine test, aimed at early detection of bladder cancer in patients. This test is a non-invasive method to analyze tumor markers in the urine of patients with hematuria and to identify patients at both low and high risk of bladder cancer.
Promis Diagnostic’s lung cancer test is a blood test to identify people with a heightened risk of lung cancer for triage into CT scanning. The test is a qualitative detection of epigenetic markers, PCDHGA12, associated with lung cancer in pulmonary nodule patients. It has been proven to be able to diagnose lung cancer with 77.8% sensitivity and specificity of 92.3% in pivotal study on 522 subjects.
Early detection of colorectal cancer based on presence of methylated syndecan-2 (SDC2) in stool DNA. Clinical Epigenetics. 2019 Mar 15;11(1):51,
Feasibility of quantifying SDC2 methylation in stool DNA for early detection of colorectal cancer. Clinical Epigenetics. 2017 4;9:126
PCDHGA12 methylation biomarker in bronchial washing specimens as an adjunctive diagnostic tool to bronchoscopy in lung cancer. Oncology Letters. 2018 Jul;16(1):1039-1045
* PromisDx products are for Research Use Only in the United States.